Get the Stockscreener App
217.13
0.80%
1.73
After Hours:
217.25
0.12
+0.06%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $217.13, with a volume of 5.66M.
It is up +0.80% in the last 24 hours and up +5.10% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$215.40
Open:
$214.8
24h Volume:
5.66M
Relative Volume:
0.86
Market Cap:
$383.62B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
107.10
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+0.80%
1M Performance:
+5.10%
6M Performance:
-5.69%
1Y Performance:
+15.96%
1-Day Range:
$213.72
$219.54
1-Week Range:
$208.99
$219.60
52-Week Range:
$181.73
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
217.13 | 380.57B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,078.78 | 948.95B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
223.24 | 536.54B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
114.70 | 285.64B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
143.66 | 273.77B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie Inc. stock (US00287Y1091): Goldman Sachs healthcare conference appearance and steady NYSE tra - AD HOC NEWS
AbbVie Delivers 400% Returns Beating The S&P 500 by 139% - Yahoo Finance
AbbVie Gets EU Nod for Aquipta as Acute Treatment for Migraine - The Globe and Mail
Investors heavily search AbbVie Inc. (ABBV): Here is what you need to know - MSN
EC approves AbbVie’s Aquipta for migraine - The Pharma Letter
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know - Yahoo Finance
AbbVie Inc stock (US00287Y1091): participation at Goldman Sachs healthcare conference in focus - AD HOC NEWS
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie (ABBV) to Attend Goldman Sachs Global Healthcare Conferen - GuruFocus
Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic - Yahoo Finance
AbbVie Inc. stock (US00287Y1091): conference appearance and EU migraine approval keep focus on pharm - AD HOC NEWS
AbbVie Inc. (ABBV) Announces EC Authorization of Expanded Label for VENCLYXTO® - Insider Monkey
AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - Investing News Network
Is AbbVie Inc. (ABBV) Expanding Its Oncology Pipeline With New BPDCN Treatment Approval? - Insider Monkey
AbbVie (ABBV) Secures EU Approval for Aquipta as Migraine Treatm - GuruFocus
State Street's Health Care ETF Tops Invesco's on Yield and Returns - The Motley Fool
AbbVie Inc stock (US00287Y1091): shares ease after recent NYSE pullback despite oncology pipeline fo - AD HOC NEWS
Important Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds AbbVie, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Significant Losses to Contact the Firm - TMX Newsfile
AbbVie Inc. stock underperforms Monday when compared to competitors - MarketWatch
AbbVie Inc. stock (US00287Y1091): shares retreat as NYSE trading turns lower despite fresh oncology - AD HOC NEWS
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Globe and Mail
AbbVie Inc. (ABBV) Stock Analysis: Evaluating a 16% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
AbbVie Inc stock (US00287Y1091): FDA approval for rare blood cancer drug in focus as NYSE trading ho - AD HOC NEWS
AbbVie Inc. stock (US00287Y1091): FDA approval for DECNUPAZ and major Norges Bank stake highlight on - AD HOC NEWS
AbbVie Inc. stock (US00287Y1091): EU label expansion for Venclyxto puts oncology focus in the spotli - AD HOC NEWS
AbbVie (ABBV) Up 3.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia - Investing News Network
AbbVie (ABBV) Expands Venclyxto Label for Chronic Lymphocytic Le - GuruFocus
AbbVie Stock: Is ABBV Outperforming the Healthcare Sector? - Barchart.com
Abbvie gets EU approval for expanded Venclyxto label in CLL By Investing.com - Investing.com Canada
AbbVie gets EU approval for expanded VENCLYXTO cancer drug combinations - StreetInsider
European Commission okays all-oral VENCLYXTO combos with time off treatment - Stock Titan
AbbVie Inc stock (US00287Y1091): shares edge higher in New York after JPMorgan adjusts outlook - AD HOC NEWS
AB Sustainable Global Thematic Portfolio's AbbVie Inc(ABBV) Holding History - GuruFocus
Hikari Power Ltd's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie Picks North Carolina for Campus - Advanced Manufacturing
AbbVie’s ADC Strategy Notches Another Win With FDA Approval in Ultra-Rare Blood Cancer - MedCity News
Future of ADCs - AbbVie
High Court revives AbbVie's arthritis drug patent application after commissioner's delay - Australasian Lawyer
AbbVie Wins FDA Nod for Decnupaz for Rare Blood Cancer Indication - Yahoo Finance
FDA greenlights AbbVie's new drug against rare blood cancer - medwatch.com
FDA clears AbbVie’s Decnupaz for rare blood cancer - The Pharma Letter
ABBV Stock Price, Quote & Chart | ABBVIE INC (NYSE:ABBV) - ChartMill
AbbVie, Inc. Shs Thailand Depositary Receipts Repr 1 Sh Trade Ideas — SET:ABBV80 - TradingView
US FDA approves AbbVie's rare blood cancer drug - Reuters
AbbVie (ABBV) Receives FDA Approval for Groundbreaking BPDCN Tre - GuruFocus
AbbVie receives FDA approval for BPDCN blood cancer treatment By Investing.com - Investing.com Australia
Ironwood, AbbVie win US label expansion for Linzess in pediatric constipation - MSN
FDA clears first outpatient BPDCN antibody-drug conjugate for rare blood cancer - Stock Titan
AbbVie (ABBV) Secures FDA Approval for Decnupaz in Rare Blood Ca - GuruFocus
US FDA approves AbbVie’s rare blood cancer drug - WKZO
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abbvie Inc Stock (ABBV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Purdue David Ryan | SVP, Controller |
Mar 04 '26 |
Sale |
233.56 |
5,230 |
1,221,519 |
2,654 |
0.82%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):